Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 56
Inquire Before Buying

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017, provides an overview of the Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline landscape.

Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below. Fever spikes often occur at approximately the same time every day. A faint salmon colored skin rash characteristically comes and goes and does not itch. Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 5 and 1 respectively.

Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).

- The pipeline guide reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Systemic Idiopathic Juvenile Arthritis - Overview
Systemic Idiopathic Juvenile Arthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development
Alteogen Inc
Johnson & Johnson
Livzon Pharmaceutical Group Inc
Mycenax Biotech Inc
Novartis AG
Oncobiologics Inc
Systemic Idiopathic Juvenile Arthritis - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Systemic Idiopathic Juvenile Arthritis - Dormant Projects
Systemic Idiopathic Juvenile Arthritis - Discontinued Products
Systemic Idiopathic Juvenile Arthritis - Product Development Milestones
Featured News & Press Releases
Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris
May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials
Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012
Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Alteogen Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Johnson & Johnson, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Novartis AG, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Oncobiologics Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Dormant Projects, H2 2017
Systemic Idiopathic Juvenile Arthritis - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Arthritis Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." The Global Arthritis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understan......
  • Global Rheumatoid Arthritis Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." The Global Rheumatoid Arthritis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provide......
  • Global Osteoarthritis Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Osteoarthritis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides unde......
  • Osteoarthritis - Pipeline Review, H2 2017
    Published: 22-Aug-2017        Price: US 2000 Onwards        Pages: 240
    Osteoarthritis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain......
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Systemic Juvenile Idiopathic Arthritis (SJIA) -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Systemic Juvenile Idiopathic Arthritis (SJIA) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Systemic Juvenile Idiopathic Arthritis (SJIA). The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs ass......
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 28-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Systemic Juvenile Idiopathic Arthritis (SJIA) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Systemic Juvenile Idiopathic Arthritis (SJIA) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current development......
  • Juvenile Rheumatoid Arthritis - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Juvenile Rheumatoid Arthritis-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Juvenile Rheumatoid Arthritis. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Juvenile Rheumatoid Arthritis by development stage, therapy type, route of administration and molecule type is......
  • Juvenile Rheumatoid Arthritis - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Juvenile Rheumatoid Arthritis -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Juvenile Rheumatoid Arthritis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Juvenile Rheumatoid Arthritis. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Juvenile Rheumatoid Arthritis. ......
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Systemic Juvenile Idiopathic Arthritis (SJIA)-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Systemic Juvenile Idiopathic Arthritis (SJIA). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Systemic Juvenile Idiopathic Arthritis (SJIA) by development stage, therapy ty......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs